Cargando…

Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP)

INTRODUCTION: Pneumonia is the most common cause of mortality from infectious diseases, the second leading cause of nosocomial infection, and the leading cause of mortality among hospitalized adults. To improve clinical management, metabolomics has been increasingly applied to find specific metaboli...

Descripción completa

Detalles Bibliográficos
Autores principales: Banoei, Mohammad M., Vogel, Hans J., Weljie, Aalim M., Yende, Sachin, Angus, Derek C., Winston, Brent W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385943/
https://www.ncbi.nlm.nih.gov/pubmed/32718333
http://dx.doi.org/10.1186/s13054-020-03147-3
_version_ 1783563868191064064
author Banoei, Mohammad M.
Vogel, Hans J.
Weljie, Aalim M.
Yende, Sachin
Angus, Derek C.
Winston, Brent W.
author_facet Banoei, Mohammad M.
Vogel, Hans J.
Weljie, Aalim M.
Yende, Sachin
Angus, Derek C.
Winston, Brent W.
author_sort Banoei, Mohammad M.
collection PubMed
description INTRODUCTION: Pneumonia is the most common cause of mortality from infectious diseases, the second leading cause of nosocomial infection, and the leading cause of mortality among hospitalized adults. To improve clinical management, metabolomics has been increasingly applied to find specific metabolic biopatterns (profiling) for the diagnosis and prognosis of various infectious diseases, including pneumonia. METHODS: One hundred fifty bacterial community-acquired pneumonia (CAP) patients whose plasma samples were drawn within the first 24 h of hospital admission were enrolled in this study and separated into two age- and sex-matched cohorts: non-survivors (died ≤ 90 days) and survivors (survived > 90 days). Three analytical tools, (1)H-NMR spectroscopy, GC-MS, and targeted DI-MS/MS, were used to prognosticate non-survivors from survivors by means of metabolic profiles. RESULTS: We show that quantitative lipid profiling using DI-MS/MS can predict the 90-day mortality and in-hospital mortality among patients with bacterial CAP compared to (1)H-NMR- and GC-MS-based metabolomics. This study showed that the decreased lysophosphatidylcholines and increased acylcarnitines are significantly associated with increased mortality in bacterial CAP. Additionally, we found that decreased lysophosphatidylcholines and phosphatidylcholines (> 36 carbons) and increased acylcarnitines may be used to predict the prognosis of in-hospital mortality for bacterial CAP as well as the need for ICU admission and severity of bacterial CAP. DISCUSSION: This study demonstrates that lipid-based plasma metabolites can be used for the prognosis of 90-day mortality among patients with bacterial CAP. Moreover, lipid profiling can be utilized to identify patients with bacterial CAP who are at the highest risk of dying in hospital and who need ICU admission as well as the severity assessment of CAP.
format Online
Article
Text
id pubmed-7385943
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73859432020-07-30 Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP) Banoei, Mohammad M. Vogel, Hans J. Weljie, Aalim M. Yende, Sachin Angus, Derek C. Winston, Brent W. Crit Care Research INTRODUCTION: Pneumonia is the most common cause of mortality from infectious diseases, the second leading cause of nosocomial infection, and the leading cause of mortality among hospitalized adults. To improve clinical management, metabolomics has been increasingly applied to find specific metabolic biopatterns (profiling) for the diagnosis and prognosis of various infectious diseases, including pneumonia. METHODS: One hundred fifty bacterial community-acquired pneumonia (CAP) patients whose plasma samples were drawn within the first 24 h of hospital admission were enrolled in this study and separated into two age- and sex-matched cohorts: non-survivors (died ≤ 90 days) and survivors (survived > 90 days). Three analytical tools, (1)H-NMR spectroscopy, GC-MS, and targeted DI-MS/MS, were used to prognosticate non-survivors from survivors by means of metabolic profiles. RESULTS: We show that quantitative lipid profiling using DI-MS/MS can predict the 90-day mortality and in-hospital mortality among patients with bacterial CAP compared to (1)H-NMR- and GC-MS-based metabolomics. This study showed that the decreased lysophosphatidylcholines and increased acylcarnitines are significantly associated with increased mortality in bacterial CAP. Additionally, we found that decreased lysophosphatidylcholines and phosphatidylcholines (> 36 carbons) and increased acylcarnitines may be used to predict the prognosis of in-hospital mortality for bacterial CAP as well as the need for ICU admission and severity of bacterial CAP. DISCUSSION: This study demonstrates that lipid-based plasma metabolites can be used for the prognosis of 90-day mortality among patients with bacterial CAP. Moreover, lipid profiling can be utilized to identify patients with bacterial CAP who are at the highest risk of dying in hospital and who need ICU admission as well as the severity assessment of CAP. BioMed Central 2020-07-27 /pmc/articles/PMC7385943/ /pubmed/32718333 http://dx.doi.org/10.1186/s13054-020-03147-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Banoei, Mohammad M.
Vogel, Hans J.
Weljie, Aalim M.
Yende, Sachin
Angus, Derek C.
Winston, Brent W.
Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP)
title Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP)
title_full Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP)
title_fullStr Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP)
title_full_unstemmed Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP)
title_short Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP)
title_sort plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, icu admission, and severity in bacterial community-acquired pneumonia (cap)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385943/
https://www.ncbi.nlm.nih.gov/pubmed/32718333
http://dx.doi.org/10.1186/s13054-020-03147-3
work_keys_str_mv AT banoeimohammadm plasmalipidprofilingfortheprognosisof90daymortalityinhospitalmortalityicuadmissionandseverityinbacterialcommunityacquiredpneumoniacap
AT vogelhansj plasmalipidprofilingfortheprognosisof90daymortalityinhospitalmortalityicuadmissionandseverityinbacterialcommunityacquiredpneumoniacap
AT weljieaalimm plasmalipidprofilingfortheprognosisof90daymortalityinhospitalmortalityicuadmissionandseverityinbacterialcommunityacquiredpneumoniacap
AT yendesachin plasmalipidprofilingfortheprognosisof90daymortalityinhospitalmortalityicuadmissionandseverityinbacterialcommunityacquiredpneumoniacap
AT angusderekc plasmalipidprofilingfortheprognosisof90daymortalityinhospitalmortalityicuadmissionandseverityinbacterialcommunityacquiredpneumoniacap
AT winstonbrentw plasmalipidprofilingfortheprognosisof90daymortalityinhospitalmortalityicuadmissionandseverityinbacterialcommunityacquiredpneumoniacap